Robert, C., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Muñoz-Couselo, E., … Wong, M. K. K. (2024). LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab. In Annals of Oncology (Vol. 35, pp. S1236–S1237). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.2287

Robert, C., M. M. Milhem, J. J. Sacco, J. Michels, G. K. In, E. Muñoz-Couselo, D. Schadendorf, et al. “LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab.” In Annals of Oncology, 35:S1236–37. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.2287.

Robert C, Milhem MM, Sacco JJ, Michels J, In GK, Muñoz-Couselo E, et al. LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab. In: Annals of Oncology. Elsevier BV; 2024. p. S1236–7.

Robert, C., et al. “LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S1236–37. Crossref, doi:10.1016/j.annonc.2024.08.2287.

Robert C, Milhem MM, Sacco JJ, Michels J, In GK, Muñoz-Couselo E, Schadendorf D, Beasley GM, Niu JJ, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai KK, Lebbe C, Gaudy Marqueste C, Middleton MR, Samson A, Zhu J, Viana M, Wong MKK. LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab. Annals of Oncology. Elsevier BV; 2024. p. S1236–S1237.